Morgan Stanley Starts Exscientia PLC (EXAI) at Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
UPDATE: BofA Securities Starts Exscientia PLC (EXAI) at Buy on AI Enabled Drug Platform
October 26, 2021 6:07 AM EDT(Updated - October 27, 2021 7:27 AM EDT)
BofA Securities analyst Michael Ryskin initiates coverage on Exscientia PLC (NASDAQ: EXAI) with a Buy rating and a price target of $27.00.
The analyst stated "Exscientia is a tech-enabled drug discovery platform company, leveraging artificial... More
